JP2021529169A5 - - Google Patents

Info

Publication number
JP2021529169A5
JP2021529169A5 JP2020570726A JP2020570726A JP2021529169A5 JP 2021529169 A5 JP2021529169 A5 JP 2021529169A5 JP 2020570726 A JP2020570726 A JP 2020570726A JP 2020570726 A JP2020570726 A JP 2020570726A JP 2021529169 A5 JP2021529169 A5 JP 2021529169A5
Authority
JP
Japan
Prior art keywords
therapeutic composition
composition according
rest
inhibitor
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020570726A
Other languages
English (en)
Japanese (ja)
Other versions
JP7555542B2 (ja
JP2021529169A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/037754 external-priority patent/WO2019246112A1/en
Publication of JP2021529169A publication Critical patent/JP2021529169A/ja
Publication of JP2021529169A5 publication Critical patent/JP2021529169A5/ja
Priority to JP2024043444A priority Critical patent/JP2024075673A/ja
Application granted granted Critical
Publication of JP7555542B2 publication Critical patent/JP7555542B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020570726A 2018-06-18 2019-06-18 統合失調症及び他の神経精神障害の治療方法 Active JP7555542B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024043444A JP2024075673A (ja) 2018-06-18 2024-03-19 統合失調症及び他の神経精神障害の治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862686346P 2018-06-18 2018-06-18
US62/686,346 2018-06-18
PCT/US2019/037754 WO2019246112A1 (en) 2018-06-18 2019-06-18 Methods of treating schizophrenia and other neuropsychiatric disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024043444A Division JP2024075673A (ja) 2018-06-18 2024-03-19 統合失調症及び他の神経精神障害の治療方法

Publications (3)

Publication Number Publication Date
JP2021529169A JP2021529169A (ja) 2021-10-28
JP2021529169A5 true JP2021529169A5 (enExample) 2022-05-19
JP7555542B2 JP7555542B2 (ja) 2024-09-25

Family

ID=67297259

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020570726A Active JP7555542B2 (ja) 2018-06-18 2019-06-18 統合失調症及び他の神経精神障害の治療方法
JP2024043444A Pending JP2024075673A (ja) 2018-06-18 2024-03-19 統合失調症及び他の神経精神障害の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024043444A Pending JP2024075673A (ja) 2018-06-18 2024-03-19 統合失調症及び他の神経精神障害の治療方法

Country Status (7)

Country Link
US (1) US20210260002A1 (enExample)
EP (1) EP3806861A1 (enExample)
JP (2) JP7555542B2 (enExample)
KR (1) KR102847197B1 (enExample)
CN (1) CN112566640A (enExample)
CA (1) CA3103663A1 (enExample)
WO (1) WO2019246112A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110011658A (ko) 2008-05-08 2011-02-08 유니버시티 오브 로체스터 최적화된 세포 제제에 의한 수초 질환의 치료
JP6541577B2 (ja) 2013-02-06 2019-07-10 ユニバーシティー オブ ロチェスター ミエリン障害の治療のための誘導多能性細胞由来オリゴデンドロサイト前駆細胞
US9724432B2 (en) 2015-04-30 2017-08-08 University Of Rochester Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder
US11690876B2 (en) 2017-05-10 2023-07-04 University Of Rochester Methods of treating neuropsychiatric disorders
CA3103675A1 (en) 2018-06-21 2019-12-26 University Of Rochester Methods of treating or inhibiting onset of huntington's disease
CN115887655B (zh) * 2021-09-30 2025-06-17 上海鲸奇生物科技有限公司 直接转分化治疗神经系统疾病
JPWO2024181416A1 (enExample) * 2023-02-28 2024-09-06
WO2025184089A1 (en) * 2024-02-29 2025-09-04 Board Of Regents, The University Of Texas System Compositions and methods of use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935811A (en) 1995-03-03 1999-08-10 California Institute Of Technology Neuron-restrictive silencer factor nucleic acids
US20080119427A1 (en) 1996-06-06 2008-05-22 Isis Pharmaceuticals, Inc. Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6838283B2 (en) 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
ES2234563T5 (es) 1999-02-12 2018-01-17 Daiichi Sankyo Company, Limited Nuevos análogos de nucleósidos y oligonucleótidos
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
US7179796B2 (en) 2000-01-18 2007-02-20 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
US20030027153A1 (en) * 2001-01-09 2003-02-06 Meyer Joanne M. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
CA2452458A1 (en) 2001-07-03 2003-01-16 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
DE60310944T3 (de) 2002-08-05 2017-08-03 Silence Therapeutics Gmbh Weitere neue formen von interferierende rns moleküle
EP1393776A1 (en) * 2002-08-14 2004-03-03 Erasmus University Medical Center Rotterdam Use of genes identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer
EP2256201A3 (en) 2003-09-18 2012-07-04 Isis Pharmaceuticals, Inc. Modulation of eIF4E expression
JP4428296B2 (ja) 2005-06-10 2010-03-10 セイコーエプソン株式会社 表示パネルモジュールおよび表示装置
US8048999B2 (en) 2005-12-13 2011-11-01 Kyoto University Nuclear reprogramming factor
JP5813321B2 (ja) 2007-03-23 2015-11-17 ウィスコンシン アラムニ リサーチ ファンデーション 体細胞の再プログラム化
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
WO2009027349A2 (en) 2007-08-24 2009-03-05 Oryzon Genomics Sa Treatment and prevention of neurodegenerative diseases
EP2315829B1 (en) 2008-08-08 2015-02-11 Mayo Foundation For Medical Education And Research Induced pluripotent stem cells
WO2011031998A1 (en) 2009-09-11 2011-03-17 Isis Pharmaceuticals, Inc. Modulation of re1 silencing transcription factor expression
WO2011062963A2 (en) 2009-11-17 2011-05-26 Vitro Diagnositics, Inc. Induced puripotent stem cells and related methods
US9005967B2 (en) 2010-01-22 2015-04-14 Kyoto University Myc variants improve induced pluripotent stem cell generation efficiency
KR101235256B1 (ko) * 2010-09-13 2013-02-21 서울대학교산학협력단 ｍｉＲＮＡ를 타겟으로 한 신경퇴행성 질환 치료

Similar Documents

Publication Publication Date Title
JP2021529169A5 (enExample)
Lau et al. An aging, pathology burden, and glial senescence build-up hypothesis for late onset Alzheimer’s disease
Wu et al. Functional roles and networks of non-coding RNAs in the pathogenesis of neurodegenerative diseases
Lee et al. miR‐206 regulates brain‐derived neurotrophic factor in Alzheimer disease model
JP2025172101A (ja) ドライアイの治療用医薬組成物
CN103189069B (zh) 以miRNA为靶的神经退行性疾病的治疗
Qin et al. Cross-talk between KLF4 and STAT3 regulates axon regeneration
US11221329B2 (en) Treatment of neurological and neurodevelopmental diseases and disorders associated with aberrant ion channel expression and activity
Hennig et al. Transcription coactivators p300 and CBP are necessary for photoreceptor-specific chromatin organization and gene expression
US10801027B2 (en) Inhibitors of SRSF1 to treat neurodegenerative disorders
JP2022511568A5 (enExample)
US12157889B2 (en) Methods to detect motor neuron disease comprising micro-RNAs
JP2022515881A (ja) オリゴ核酸分子及びその応用
Li et al. Ube2c-inhibition alleviated amyloid pathology and memory deficits in APP/PS1 mice model of AD
Fang et al. Silencing miR-155–5p alleviates hippocampal damage in kainic acid-induced epileptic rats via the Dusp14/MAPK pathway
US20200071699A1 (en) Treatment of alzheimers disease with micro rna and ghrelin
Gomaa et al. Prasugrel anti-ischemic effect in rats: modulation of hippocampal SUMO2/3-IкBα/Ubc9 and SIRT-1/miR-22 trajectories
KR20250109188A (ko) 알츠하이머병 및 기타 뇌 질환을 치료하는 조성물 및 방법
Yuan et al. Upregulation of miR-424 inhibit retinal endothelial cells proliferation under high glucose condition via cyclin D1.
JP2024503503A (ja) 認知機能障害を治療するためのマイクロｒｎａ １９５組成物及び方法
Bayram et al. Decreased hdac1 gene expression in patients with alzheimer’s disease
CN112779252B (zh) 靶向SMN2启动子区MeCP2结合的关键甲基化区域的反义寡核苷酸
Schroeder et al. Genetic and pharmacological reversibility of phenotypes in mouse models of autism spectrum disorder
WO2025264967A1 (en) Agents and/or compositions useful for modulating cis-regulatory elements in synucleinopathies and methods for identifying agents and compositions thereof
CN118217303A (zh) miR-4763-3p或其拮抗剂在制备用于缓解/治疗认知衰退的药物中的应用